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Deficiency of Parkinson’s disease-related gene Fbxo7
is associated with impaired mitochondrial metabolism
by PARP activation
Marta Delgado-Camprubi1,2, Noemi Esteras1,2, Marc PM Soutar1, Helene Plun-Favreau*,1,3 and Andrey Y Abramov*,1,3
The Parkinson’s disease (PD)-related protein F-box only protein 7 (Fbxo7) is the substrate-recognition component of the Skp1-
Cullin-F-box protein E3 ubiquitin ligase complex. We have recently shown that PD-associated mutations in Fbxo7 disrupt
mitochondrial autophagy (mitophagy), suggesting a role for Fbxo7 in modulating mitochondrial homeostasis. Here we report that
Fbxo7 deficiency is associated with reduced cellular NAD+ levels, which results in increased mitochondrial NADH redox index and
impaired activity of complex I in the electron transport chain. Under these conditions of compromised respiration, mitochondrial
membrane potential and ATP contents are reduced, and cytosolic reactive oxygen species (ROS) production is increased. ROS
activates poly (ADP-ribose) polymerase (PARP) activity in Fbxo7-deficient cells. PARP inhibitor restores cellular NAD+ content and
redox index and ATP pool, suggesting that PARP overactivation is cause of decreased complex I-driven respiration. These findings
bring new insight into the mechanism of Fbxo7 deficiency, emphasising the importance of mitochondrial dysfunction in PD.
Cell Death and Differentiation (2017) 24, 120–131; doi:10.1038/cdd.2016.104; published online 30 September 2016
Mitochondrial susceptibility to age-related oxidative stress
makes mitochondrial impairment a common feature of
neurodegeneration.1 Parkinson’s disease (PD) is the most
common neurodegenerative movement disorder affecting 1%
of the world population above the age of 60.2 Evidence of
mitochondrial dysfunction in PD derives from mitochondrial
toxin-induced models of the disease,3,4 and from the
observation of mitochondrial abnormalities in post-mortem
tissue from patients with idiopathic PD.5–7 Mutations in
disease-related genes encoding for proteins with a mitochon-
drial function have also been identified, further suppo-
rting the conclusion that mitochondrial impairment is a
hallmark of PD.8–11
Mutations in the F-box only protein 7 gene (Fbxo7; PARK15)
cause autosomal recessive juvenile atypical Parkinsonism
with pyramidal syndrome.12 Fbxo7 belongs to a sub-class
of F-box proteins (FBPs) that function as adaptors for the
Skp1-Cullin-F-box (SCF) class of ubiquitin E3 ligases. SCF
complexes are involved in the phosphorylation-dependent
ubiquitination of proteins targeted for proteasomal
degradation.13 FBPs determine the specificity of the substrate
to be ubiquitinated by bringing the substrate into proximity with
the SCF complex.14 In addition to SCF-dependent activities,
several FBPs participate in cellular functions, including cell
cycle regulation and mitochondrial dynamics.15 We have
recently shown that, together with the PD-associated proteins,
PTEN-induced putative kinase 1 (PARK6) and Parkin
(PARK2), Fbxo7 regulates the selective autophagic clearance
of depolarised mitochondria (mitophagy). Although predomi-
nantly detected at the mitochondria upon depolarisation, a
small proportion of Fbxo7 is present in non-depolarised
mitochondria, suggesting a potential role for Fbxo7 in
regulating basal mitochondrial homeostasis.16
Poly (ADP-ribose) (PAR) polymerase (PARP) enzymes
activate DNA repair in response to oxidative damage by
mediating the attachment of PAR polymers on itself and other
proteins. The PARP family includes 18 members, among
which PARP-1 (hereafter referred as PARP) is responsible for
the 80% of the NAD+-dependent synthesis of PAR polymers.17
PARP prolonged activation can, however, cause a reduction
of cellular NAD+, which in turn can lead to ATP reduction
and bioenergetic collapse.18 PARP-activated NAD+ depletion
has been associated before with the pathogenesis of
neurodegenerative disorders, in particular with Alzheimer’s
disease19–21 and glutamate excitotoxicity.22,23
In this study, we sought to investigate the mitochondrial
pathophysiology associated with Fbxo7 deficiency in Fbxo7
knockdown (KD) human dopaminergic neuroblastoma SH-
SY5Y cells and in patient fibroblasts harbouring the homo-
zygous R378G pathogenic mutation in Fbxo7. We report that
Fbxo7 deficiency is associated with cellular NAD+ depletion,
limiting NADH substrate for complex I in the mitochondrial
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electron transport chain (ETC). Fbxo7 deficiency results in
impaired complex I-linked respiration, limited maximal oxygen
rate capacity and mitochondrial depolarisation. We found that
Fbxo7 deficiency leads to the activation of PARP.We show that
PARP pharmacologic inhibition increases cellular NAD+
levels, and restores NADH redox index and complex I NADH
dehydrogenase activity that results in recovery of the ATP pool
in Fbxo7-deficient cells. Our findings suggest that PARP
overactivation may cause mitochondrial dysfunction in Fbxo7-
deficient cells.
Results
Mitochondrial membrane potential and ATP levels are
reduced in Fbxo7-deficient cells. Mitochondrial membrane
potential (ΔΨm) can be measured using tetramethylrhoda-
mine methyl ester (TMRM) to estimate mitochondrial function
and cell health.24 Whenever possible, all experiments were
performed in two different cell models of Fbxo7 deficiency
(patient’s fibroblasts and KD SH-SY5Ys), in order to exclude
any artefact due to a particular cell genetic background. To
study Fbxo7’s role in mitochondrial maintenance, ΔΨm was
measured in a stable Fbxo7 KD SH-SY5Y cell line and in a
fibroblast line derived from a PD patient with the Fbxo7
R378G mutation (Figure 1ai–ii). In both models, Fbxo7
deficiency was associated with a significant reduction
in the TMRM fluorescence as compared with controls
(Figure 1bi; 15.6±3.6% reduction, n=4, Po0.05;
Figure 1bii; 37.6±5.4% decrease compared to control 1,
n= 4, Po0.05; 48.9± 22.5% decrease compared with control
2, n= 4; Po0.05). The level of Fbxo7 KD was estimated at
90% by western blot (WB; Supplementary Figure S1Ai).
When the proton pumps of the ETC are not sufficient to
maintain ΔΨm, the ATP synthase can work in reverse mode
to sustain the proton gradient by ATP hydrolysis.25,26
To investigate the mechanism of ΔΨm maintenance in Fbxo7
deficiency, cells were treated with different mitochondrial
toxins. Treating control and Fbxo7-deficient cells with 2 μg/ml
of oligomycin, an inhibitor of the F1F0-ATP synthase, caused
no depolarisation, indicating that the ATP synthase is not
working in reverse mode. Subsequent addition of complex I
inhibitor, rotenone (5 μM), resulted in a profound depolarisa-
tion, followed by a complete depolarisation after addition of the
mitochondrial uncoupler carbonylcyanide-p-trifluoromethoxy-
phenylhydrazone (FCCP; 1 μM). These data indicate that in
Fbxo7-deficient cells, ΔΨm is maintained by the ETC activity
as opposed to ATP hydrolysis (Supplementary Figure S1B).
Reduction in ΔΨm may suggest a disruption of the ATP
content, which was reduced in Fbxo7KDSH-SY5Y cells when
compared with scrambled (scr) cells (Figure 1ci; 14± 4.5%
reduction; n=3; Po0.05). ATP levels were significantly
decreased in fibroblasts carrying the Fbxo7 mutation as
compared with control fibroblasts (Figure 1cii; 21± 6.8%
reduction compared with control 1, n=5, Po0.05;
47.1±6.8% reduction compared with control 2, n= 3,
Po0.05), indicating that Fbxo7 deficiency is associated with
decreased cellular ATP levels.
Oxygen consumption is disrupted in Fbxo7 KD SH-
SY5Ys. A reduction in ΔΨm and cellular ATP in Fbxo7-
deficient cells suggests a potential respiratory defect. To
investigate the cell respiratory activity, the rate of oxygen
consumption was measured using a Clark oxygen electrode in
a clonal population of cells stably expressing scr or Fbxo7
shRNA. Rates of basal oxygen consumption were similar in
scr and in Fbxo7 KD cells (Figure 2a; 2.4±0.4 ng O/min/106
scr cells; 2.6±0.2 ng O/min/106 KD cells, n=12). Addition of
oligomycin (2 μg/ml) inhibited oxygen consumption in both cell
types to a similar extent (Figure 2a; 0.6±0.1 ng O/min/106 scr
cells; 0.8±0.1 ng O/min/106 KD cells, n=11), indicating that
neither inhibition of respiration nor uncoupling under basal
conditions occurs in Fbxo7-deficient cells. Subsequent treat-
ment with FCCP (1 μM) induced an increase in oxygen
consumption in scr and in Fbxo7 KD SH-SY5Ys, but only to
a much lesser extent in the later (Figure 2a; 14.4±2.2 ng O/
min/106 scr cells; 6.1±1.2 ng O/min/106 KD cells; n=7,
Po0.01), indicating that Fbxo7 deficiency is associated with
reduced maximal rates of oxygen consumption.
To further investigate the ETC activity and its coupling to
oxidative phosphorylation, oxygen consumption was exam-
ined in detergent-permeabilised SH-SY5Ys (40 μM digitonin).
Cell permeabilisation allows the study of the individual
contribution of specific respiratory complexes to respiration
in the presence of their substrates.24 To measure the rate of
oxygen consumption in state III (V3; ADP-stimulated respira-
tory state) and state IV (V4), 50 nmol ADP was added
following the addition of complex I substrates (5 mM glutamate
and 5 mMmalate) or complex II substrates (5 mM succinate in
the presence of 5 μM rotenone). V4 is the respiratory rate
reached after state III when added ADP is consumed and the
rate of oxygen consumption returns close to pre-ADP values.
The respiratory control ratio (RCR) is calculated as the ratio
V3/V4, and is an indication of the degree of coupling between
respiration and oxidative phosphorylation. The RCR showed
no significant difference between both cell populations,
confirming that loss of Fbxo7 is not associated with
mitochondrial uncoupling (Figure 2b; 1.9± 0.03 V3/V4 in scr
cells; 1.9±0.2 V3/V4 in KD cells after addition of glutamate,
n=3; 1.5± 0.1 V3/V4 in scr cells; 1.7±0.1 V3/V4 in KD cells
after addition of succinate, n= 3). Rates of respiration in V3
and V4 were also similar in the presence of succinate in
control and KD cells (Figures 2c and d; V3: 122±23.4 ng O/
min/106 scr cells; 149.6±34.4 ng O/min/106 KD cells; V4:
85.5± 10.9 ng O/min/106 scr cells; 101.1±16.9 ng O/min/106
KD cells; n=3). However, V3 and V4 respiration rates were
significantly reduced in the presence of glutamate or malate in
Fbxo7 KD cells when compared with control cells (Figures 2c
and d; V3: 237.6±21.8 ng O/min/106 scr cells;
136.6±14.2 ng O/min/106 KD cells, n= 4, Po0.01; V4:
127.9±11.5 ng O/min/106 scr cells; 67.4± 9.1 ng O/min/106
KD cells; n=4, Po0.01), indicating that, though coupled,
Fbxo7-deficient cells have reduced complex I-driven
respiration.
Fbxo7 deficiency is associated with lower NADH
dehydrogenase activity and increased cytosolic ROS
production. Possible reasons for complex I respiratory
impairment include a reduction in protein expression or a
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decrease in its enzymatic activity. To investigate complex I
protein levels in Fbxo7-deficient cells, cell lysates from Fbxo7
KD SH-SY5Ys and from PD patient fibroblasts were assessed
by WB using a cocktail of antibodies directed against subunits
of complexes I–V of the ETC. No difference in the protein
expression of these complexes subunits was detected
between Fbxo7-deficient cells and controls (Figure 3a),
indicating that impaired respiration associated with Fbxo7
deficiency is not related to reduced expression of the ETC
proteins. The decrease in complex I-driven respiration
observed in whole and permeabilised Fbxo7-deficient cells
might, however, arise from a reduction in complex I activity.
Figure 1 Mitochondrial membrane potential and cellular ATP levels are reduced in Fbxo7-deficient cells. (a)ΔΨmwas assessed using TMRM (25:nM) in (ai) control and (aii)
patient fibroblasts, carrying a homozygous Fbxo7 R378G mutation and SH-SY5Y cells stably expressing either scr or Fbxo7 shRNA (data not shown). (b) Histograms represent
average TMRM intensity in SH-SY5Y cells (bi) and patients fibroblasts (bii) normalised to control cells, respectively. Data are represented as mean±S.E.M. from four
independent experiments. In all cases, * indicates Po0.05 compared with control values. The specificity of Fbxo7 antibody and KD were confirmed by WB (Supplementary
Figure S1A). (c) Total ATP levels were determined using a luciferase assay kit (Vialight plus assay kit (Lonza, Verviers, Belgium)) based on the bioluminescent measurement of
ATP and samples were referred to an ATP standard curve. Histograms represent average ATP levels per protein concentration, normalised to control cells in SH-SY5Y cells stably
expressing either (ci) scr or Fbxo7 shRNA, and (cii) control and patient fibroblasts with Fbxo7 R378G mutation. Data are represented as mean± S.E.M. from three (SH-SY5Ys)
and five (fibroblasts) independent experiments; *Po0.05
Mitochondrial dysfunction in Fbox7 deﬁciency
M Delgado-Camprubi et al
122
Cell Death and Differentiation
Complex I NADH dehydrogenase activity was measured
kinetically over 30 min and the rate was determined as
changes in optical density over time. A significant decrease
in complex I activity was observed in Fbxo7 KD cells when
comparedwith control cells (Figure 3bi; 22.6±5.4% decrease;
n= 5; Po0.01). The linear rate of absorbance increase in
patient fibroblasts was also reduced compared to control cells
(Figure 3bii; 50.9±2.5% decrease compared with control 1,
n= 3, Po0.01; 56.7± 2.5% decrease compared to control 2,
n= 3; Po0.01). These data indicate that Fbxo7 deficiency is
associated with altered NADH dehydrogenase activity of
isolated complex I.
Studies in various models have shown that complex I
respiratory impairment is associated with increased reactive
oxygen species (ROS) production.27–29 To investigatewhether
ROS levels are increased in Fbxo7 deficient cells, cytosolic
ROS production was measured in live cells using the
fluorescent indicator dihydroethidium (DHE; Figure 3c). Basal
level of cytosolic ROS production was significantly higher in
Fbxo7 KD SH-SY5Ys and in patient fibroblasts as compared
with controls (Figure 3di; 1.01± 0.4 increase in KD cells; n=8;
Po0.05; Figure 3dii; 0.57±0.3 increase in mutant fibroblasts
compared to control 1; n=7; Po0.05).
Mitochondrial NADH and FAD redox states are altered,
and cellular NAD+ content is reduced in Fbxo7-deficient
cells. To further investigate the cause of reduced complex I
activity in Fbxo7-deficient cells, we examined whether this may
arise from a limited NADH supply to complex I in these cells.
NADH is the electron donor for complex I, and as such, NADH
levels correlate inversely with respiratory chain activity,
although FADH reflects complex II activity (measured as FAD
autofluorescence). In order to measure redox indexes, we
added FCCP (1 μM) to maximise respiration and thus minimise
the NADH pool (and maximise FAD), then added NaCN (1 mM)
to block mitochondrial respiration and therefore maximise the
NADH pool (and minimise FAD). The initial NADH or FAD
autofluorescence (or redox state) is then calculated as a
percentage of this range (Figure 4a–c). In addition, the total
mitochondrial pool of NADH or FAD (maximum autofluores-
cence minus minimum) may be taken as an indication of the
substrate availability for complexes I and II, respectively.30,31
NADH redox index was higher in Fbxo7 KD SH-SY5Ys
and in patient fibroblasts as compared with controls
(Supplementary Figure S2A; 72.9± 3.2% in SH-SY5Y Fbxo7
KD cells; 53.6±1.9% in scr cells, n=14; Po0.001;
Supplementary Figure S2Aii; 50.6±4.5% in patient fibro-
blasts; 31.7± 2.7% in control 1; 32.7±3% in control 2, n=14;
Po0.01), indicating that the NADH redox index is closer to the
maximally reduced state in Fbxo7-deficient cells. These
results are consistent with a possible decreased complex I
respiration rate. The FAD++ redox index was also increased in
Fbxo7 KD SH-SY5Ys as compared with scr cells (Figures 4c
and d; 72.9± 7.8% in Fbxo7 KD cells; 31.6± 2.5% in scr cells,
n=4; Po0.01), indicating an increase in complex II activity,
possibly to counteract complex I deficiency. It was not possible
to measure FAD++ autofluorescence in fibroblasts due to their
low levels of FAD++ autofluorescence.
Figure 2 Oxygen consumption is disrupted in Fbxo7 KD SH-SY5Y cells. (a) Rate of oxygen consumption was measured using a Clark oxygen electrode in SH-SY5Y cells,
expressing either scr or Fbxo7 shRNA under basal conditions and following addition of oligomycin (2 μg/ml) and FCCP (1 μM). Cells were permeabilised with digitonin (40 μM)
before measuring oxygen consumption in state III (ADP stimulated) (c) and state IV (no ADP present) (d) in the presence of substrates for complex I (glutamate and malate,
5 mM) or complex II (succinate 5 mM in the presence of rotenone 5 μM). (b) RCR (the ratio of state III to state IV) was calculated for control and Fbxo7 KD SH-SY5Y cells. Data
are represented as mean±S.E.M. from at least three independent experiments; ** indicates Po0.01, NS, not significant compared with control values
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Figure 3 Fbxo7 deficiency is associated with lower NADH dehydrogenase activity and increased cytosolic ROS production. (a) Lysates from SH-SY5Y cells expressing either
scr or Fbxo7 shRNA (ai) and control and patient fibroblasts with Fbxo7 R378G mutation (aii) were assessed by WB using a cocktail of antibodies against complex I subunit
NDUFB8, complex II subunit 30 kDa, complex III core protein 2, complex IV subunit I and complex V α subunit. Complex IV is not detected in cell lysates heated at 100 °C.
Abbreviations: CI, complex I; CII, complex II; CIII, complex III; CV, complex V. The experiment was performed three times in independent days. (b) Histograms represent average
complex I NADH dehydrogenase activity, as measured by rate of increase in absorbance OD450, normalised to control cells from five independent experiments in (bi) SH-SY5Y
cells and three in (bii) fibroblasts. Data are represented as mean±S.E.M.; **P40.01. (c) The rate of cytosolic ROS production was assessed by measuring the rate of increase
in fluorescence at 530 nm/380 nm in SH-SY5Y cells expressing either (ci) scr or Fbxo7 shRNA and (cii) control and patient fibroblasts with Fbxo7 R378G mutation loaded with
DHE (80 μM). (d) Histograms represent the mean rate of increase in DHE fluorescence in (di) SH-SY5Y cells and (dii) fibroblasts, expressed as a percentage of control,±S.E.M.
from at least seven independent experiments; *Po0.05
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The NADH mitochondrial pool was significantly lower in
Fbxo7 KD cells when compared with scr cells (Figure 4di;
38.9±13% decrease; n= 4; Po0.01), and in patient fibro-
blasts when compared with control fibroblasts (Figure 4dii;
15.6± 2.9% decrease; n= 12; Po0.05), indicating a decrease
in NADHoxidation. FAD++mitochondrial pool was increased in
Figure 4 For caption please refer page 126
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Fbxo7 KD cells (Figure 4f; 43±15.7% increase; n=3),
indicating an increase in FADH2 oxidation. This increase could
result from increased complex II activity to compensate for
complex I impairment. The reduction in NADH mitochondrial
pool may result from impairment upstream of the ETC. One
possibility is that the cellular NAD+ pool available to generate
NADH in the tricarboxylic acid cycle may be decreased.
A colorimetric cell-based assay kit (Cayman Chemical, Ann
Arbor, MI, USA) was used to determine cellular NAD+ levels in
Fbxo7-deficient cells. In both Fbxo7 KD SH-SY5Ys and in
patient fibroblasts, NAD+ levels were decreased when
compared with controls (Figure 4gi; 46.9±10.8% decrease
in Fbxo7 KD SH-SY5Ys compared with scr cells; n=7;
Po0.001; Figure 4gii; 50.7±6.2% decrease in patient
fibroblasts compared with control 1 and 57.5±6.2% decrease
compared with control 2; n=8; Po0.01), suggesting that
decreased cellular NAD+ pool may be the reason for
decreased complex I-driven respiration in these cells.
DPQ PARP inhibitor increases cellular NAD+ pool and
restores NADH redox index in Fbxo7-deficient cells.
NAD+-consuming proteins include PARPs, whose function
has been described to play a role in energy metabolism, cell
survival and aging.19,32 Although PARP activity is important
for cell survival, sustained activation can compromise NAD+
bioavailability and deplete intracellular levels, eventually
leading to metabolic collapse and cell death.33–36 Accord-
ingly, PARP inhibitors such as 3,4-dihydro-5-[4-(1-piperidinyl)
butoxyl]-1(2H)-isoquinolinone (DPQ), have been described to
have a protective function in inflammatory and ischaemia-
related disorders.37–39
To investigate whether the observed increase in NADH
redox index and reduction in NAD+ content in Fbxo7-deficient
cells was a result of PARP upregulation, SH-SY5Ys and
fibroblasts were treated for 24 h with DPQ (10 μM), before the
measurement of the cellular NAD+ pool and NADH redox
index. DPQ treatment resulted in a significant increase in
cellular NAD+ content in SH-SY5Ys (Figure 5ai; 121± 35.1%
increase in treated Fbxo7 KD cells compared with non-treated
KD cells; n=4;Po0.01), and in patient fibroblasts (Figure 5aii;
43.2±9.5% increase in treated patient fibroblasts compared
with non-treated patient fibroblasts, n=6; Po0.01). DPQ
treatment also resulted in a significant decrease in NADH
redox index in Fbxo7 KD SH-SY5Ys and a decrease in patient
fibroblasts to similar levels found in non-treated control
cells (Figure 5bi; 24.2± 2.7% decrease in DPQ-treated KD
cells compared with non-treated KD cells, n=9; Po0.01.
Figure 5bii; 9.8±3.7% decrease in DPQ-treated patient
cells compared with non-treated patient fibroblasts; n= 12).
Treatment with DPQ resulted in a significant increase of
mitochondrial NADH pool in Fbxo7 KD cells and in patient
fibroblasts (Figure 5ci; 82± 13.1% increase in DPQ-treated
Fbxo7 KD cells compared with KD non-treated cells, n=4,
Po0.01. Figure 5cii; 15.7±5.7% increase in DPQ-treated
patient fibroblasts compared with non-treated patient fibro-
blasts, n=12, Po0.05). These data show that PARP inhibition
restores cellular NAD+ pool and NADH redox index in Fbxo7-
deficient cells, suggesting that PARP upregulation is the likely
cause of complex I-reduced respiration in these cells.
In order to confirm these results, we measured the protein
levels of PARP in control andFbxo7KDcells byWB.We found no
difference in protein level between Fbxo7-deficient and control
cells (Figure 5di–ii). PARP activity in Fbxo7 KD cells was
significantly higher than in control cells (113.17±0.87%of control;
n=4;Po0.05; Figure 5ei). Similar effect was also observed in the
mutant fibroblasts (125.40±3.79%, n=4; compared to control 1,
104.67±4.46, Po0.05; and control 2, 95.33±4.46, Po0.01;
Figure 5eii). Importantly, inhibitor DPQ (10 μM) blocked this
overactivation in Fbxo7-deficient cells (Figure 5ei–ii).
DPQ restores complex I activity in Fbxo7-deficient cells.
To investigate whether PARP upregulation is the cause for
decreased complex I activity in Fbxo7 deficiency, SH-SY5Ys
and fibroblasts were treated for 24 h with DPQ (10 μM) before
measuring complex I NADH dehydrogenase activity. Com-
plex I activity after DPQ pre-treatment was increased in
Fbxo7 KD cells to similar levels of scr non-treated cells
(Figure 6ai; 5.1± 7% difference compared to scr non-treated
cells, n=3). Complex I activity in patient fibroblasts was also
significantly increased after DPQ treatment (Figure 6aii;
48±5.5% increase compared with non-treated patient cells;
n= 3; Po0.01). These data indicate that reduced complex
I-driven respiration in Fbxo7-deficient cells is caused by
PARP upregulation and that inhibition of PARP activity
restores complex I NADH dehydrogenase activity.
Inhibition of PARP restores ATP pool in Fbxo7-deficient
cells. We next investigated the effect of Fbxo7 deficiency
and role of the PARP on cellular ATP levels. Mag-Fura is a
fluorescent chelator of divalent cations, with a high affinity for
magnesium and a much lower affinity for calcium. Consider
this it can be used both to investigate ATP levels in individual
cells, as ATP binds magnesium and therefore ATP levels are
inversely proportional to free magnesium, and to investigate
cytotoxicity in response to ATP depletion, as under these
conditions the cell is no longer able to maintain its ionic
Figure 4 Loss of Fbxo7 function affects mitochondrial NADH and FAD++ redox states, and reduces cellular NAD+ content in Fbxo7 KD SH-SY5Y cells. (a) The mean of NADH
representative traces is shown for SH-SY5Y cells expressing either scr (n415 cells; ai) or Fbxo7 shRNA (n415 cells; aii) following addition of FCCP (1 μM) and NaCN (1 mM).
(b) Redox index was calculated as a % of the min and max of autofluorescence in SH-SY5Y cells and fibroblasts. (c) FAD++ representative mean traces (n420 cells) are shown
for SH-SY5Y cells either expressing scr or Fbxo7 shRNA following addition of FCCP (1 μM) and NaCN (1 mM). (d) FAD redox index was calculated as a % of the min and max of
autofluorescence in scr and Fbxo7 KD SH-SY5Y cells. (e) Mitochondrial NADH pool was calculated and normalised to control SH-SY5 cells and control fibroblasts. (f)
Mitochondrial FAD++ pool was calculated and normalised to control cells. Transient Fbxo7 KD was confirmed by WB (S2B). Data are represented as mean± S.E.M. from at least
three independent experiments; *Po0.05; **Po0.01; ***Po0.005; NS, not significant. (g) Total NAD+ levels were determined measuring the increase in absorbance at 450 nm
based on the formation of formazan coupled to the reduction of NAD+ and samples were referred to a NAD+ standard curve. Histograms represent average cellular NAD+
content±S.E.M per protein concentration normalised to control cells in SH-SY5Y cells stably expressing either (gi) scr or Fbxo7 shRNA and (gii) control, and patient fibroblasts
with Fbxo7 R378G mutation; **Po0.01; *Po0.05; n47 independent experiments. i - representing data for SH-SY5Y cells, ii - data for patients fibroblasts
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homeostasis and floods with calcium.40,41 A sharp rise in
Mag-Fura ratio therefore indicates a bioenergetic collapse.
Application of 1 mM NaCN (inhibitor of mitochondrial respira-
tion) and inhibitor of glycolysis iodoacetic acid (IAA; 100 μM)
completely blocked ATP production in these cells.
Consumption of ATP in cells led to depletion of ATP pool
and then cell collapse, which can be recorded as a massive
increase in Mag-Fura ratio (Figure 6bi). In agreement with
[ATP] data presented in Figure 1c, we found that Fbxo7 KD
cells have a shorter time to collapse (54.01±1.92 min,
Figure 5 For caption please refer page 128
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n= 41 cells) compared with control (68.60±1.87 min, n=89
cells; Po0.01; Figure 6bii). Treatment with the PARP inhibitor
DPQ (10 μM) significantly delayed the time to cell collapse after
inhibition of ATP production (to 74.16±2.44 min, n=42 cells;
Figure 6bi–ii), suggesting restoration of ATP pool in these cells.
Discussion
Complex I deficiency has been reported in various tissues
from patients with idiopathic PD.42 PARP upregulation has
been previously implicated in PD pathogenesis and its
inhibition has been shown to protect against cytotoxicity in the
MPTP model of PD.43–45 PARP-mediated cell death has also
been associated with mitochondrial dysfunction,46,47 though
the downstream events of PARP activation remain to be fully
characterised. Previous studies have reported that prolonged
PARP activation results in inhibition of the glycolytic pathway
caused by a reduction in NAD+ content, which subsequently
compromises respiration where NADH is a key cofactor.33,48
We also show that in Fbxo7KDSH-SY5Ys and R378Gmutant
fibroblasts, NAD+ levels are reduced and can be restored
after DPQ treatment, strongly suggesting that a limitation in
Figure 5 Fbxo7 deficiency increased PARP activity; PARP inhibitor DPQ restored NAD+ pool, NADH redox index and mitochondrial NADH pool in these cells. (a) Cellular
NAD+ levels were measured using a colorimetric cell-based assay kit. Histograms represent average cellular NAD+ content±S.E.M per protein concentration normalised to
control cells in (ai) SH-SY5Y cells stably expressing either scr or Fbxo7 shRNA, and (aii) control and patient fibroblasts treated with either DMSO or DPQ for 24 h. (b) Histograms
represent the mean of the mitochondrial redox index in SH-SY5Y cells expressing either (bii) scr or Fbxo7 shRNA, and (bii) control and patient fibroblasts with Fbxo7 R378G
mutation. (c) Mitochondrial NADH pool was calculated and normalised to control cells for (ci) Fbxo7 KD SH-SY5Y cells and (cii) patient fibroblasts. In all cases ** indicates
Po0.01; *Po0.05; NS, not significant; n44 independent experiments. (d) PARP enzyme levels were assessed by western blot in cell lysates from SH-SY5Y, expressing either
Scr or Fbxo7 shRNA (di) and in fibroblasts from control individuals and a patient with Fbxo7 R378G mutation (dii). Only one band was detected, corresponding to full length PARP.
(e) PARP1 activity was measured using the HT Colorimetric PARP/Apoptosis Assay from Trevigen (Gaithersburg, MD, USA), as described in Methods, in SHSY5Y cells (ei) and
fibroblasts (eii) treated with vehicle (DMSO) or PARP1 inhibitor DPQ 10 μM for 24 h. Results were normalised to PARP activity of control in every experiment. In all cases data are
represented as mean±S.E.M.; ** indicates Po0.01; *Po0.05; n.s, not significant; n≥ 4 independent experiments
Figure 6 DPQ PARP inhibitor restores NADH dehydrogenase activity of isolated complex I and increases ATP pool in Fbxo7-deficient cells. (a) Complex I NADH
dehydrogenase activity was measured kinetically over 30 min and the rate was determined as change in optical density over time. Rate of complex I activity was calculated and
normalised to control cells for (ai) Fbxo7 KD SH-SY5Y cells and (aii) patient fibroblasts; **Po0.01. The experiment was performed n43. Data are represented as mean±
S.E.M. (b) ATP levels were assessed using the Mg2+ indicator Mag-Fura. Inhibition of ATP production by blocking mitochondrial respiration with 1 mM NaCN and glycolysis with
100 μM iodoacetic acid (IAA) induced a consumption of ATP resulting in slow increase in Mag-Fura ratio and bioenergetic cell collapse, when ATP is completely depleted (which
resulted in high increase in Mag-Fura ratio due to calcium overload). Representative traces of the experiment are shown in (bi). Time to collapse was calculated for each condition
and represented in (bii) (data represent mean±S.E.M, **Po0.01)
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NAD+ bioavailability is associated with PARP-linked
respiratory impairment. Another study, however, has reported
that the bioenergetic collapse following PARP activation
is not dependent on NAD+ depletion, but instead on reduced
glycolysis through PAR-dependent hexokinase inhibition.49
This has then been confirmed by another study showing
that PARP-mediated PAR synthesis results in reduced
glycolysis and ATP loss.50 PARP activity has also been
suggested to reduce respiration by direct influence
on the enzymatic activity of mitochondrial proteins.51,52
Though PARP localisation is predominantly nuclear, PARP
and PARylation events have been detected at the
mitochondria.51,52 Regardless of the glycolytic maintenance,
heterologous expression of a truncated active form of PARP
containing a MTS has been shown to cause accumulation of
mitochondrial PARylation and inhibit respiration, suggesting
that PARP activity on its own is sufficient to cause mitochon-
drial dysfunction.52
PARP-associated mitochondrial dysfunction can also result
from inhibition of other enzymes implicated in the regulation of
energy balance. Sirtuin1 (SIRT1) stimulates mitochondrial
biogenesis by regulation of PGC-1α,53 and has been linked
with mitophagy by direct deacetylation of autophagy media-
tors and deacetylation of the FOXO family of transcription
factors.54,55 SIRT3 deacetylates ETC proteins, including
complex I,56,57 and modulates hexokinase II dissociation from
the mitochondria increasing oxidative phosphorylation.58
Excessive PARP activation has been reported to repress
SIRTactivity by depletion of cellular NAD+ or by transcriptional
downregulation.59 Complex I-driven respiration in Fbxo7-
deficient cells may thus not only result from direct PARylation
and PARP-mediated cellular NAD+ decrease, but also from its
effect on substrate PARylation and SIRTactivity.
Fbxo7 deficiency is associated with mitochondrial dysfunc-
tion, either through impairment of mitochondrial respiration or
accumulation of defective mitochondria via impaired mito-
phagy, it is plausible that PARP upregulation is a common
downstream effect of one or more of these impaired
mitochondrial mechanisms in Fbxo7 deficiency, where ROS
dependent (mitochondrial) DNA damage may be active.
These findings suggest PARP inhibitors as a potential drug
treatment in PD and other mitochondria-associated neurode-
generative disorders.
Materials and Methods
Cell culture. SH-SY5Y cells were purchased from the European Collection of
Cell Cultures (Health Protection Agency, Salisbury, UK) and cultured at 37 °C and
5% CO2 in Dulbecco’s modified Eagle medium (DMEM) containing high glucose,
sodium pyruvate and 2 mM L-glutamine, (Invitrogen, Carlsbad, CA, USA),
supplemented with 10% (v/v) foetal bovine serum (FBS; PAA). With informed
consent, fibroblasts were obtained from an upper arm punch biopsy taken from
healthy and an affected individual carrying the homozygous Fbxo7 R378G mutation.
The tissue was dissected and cultured in 5 cm2 Petri dishes until fibroblasts grew
confluent enough to be transferred and cultured in larger culture vessels containing
DMEM with GlutaMAX, high glucose, sodium pyruvate and supplemented with 10%
(v/v) FBS (PAA) and 1% streptomycin (Sigma-Aldrich, St. Louis, MO, USA). Where
indicated, cells were treated with 10 μM DPQ for the appropriate time period before
harvesting lysates or live imaging.
Construct generation. Transient scr and Fbxo7 KD SH-SY5Y cells were
generated by transfecting either non-targeting scramble siRNA or a pool of four
siRNA constructs targeting human Fbxo7 (siGenome SMARTpool) using
Dharmafect transfection reagent (Dharmacon, Lafayette, CO, USA; Thermo Fisher
Scientific, Waltham, MA, USA). Scr and Fbxo7 KD shRNA SH-SY5Y cells were
produced by retroviral infection with two independent miR30-based short hairpin
constructs against either bp 387–404 or bp 444–460 of Fbxo7 isoform 1 (constructs
generated in-house38). Silencing was maintained in stable cell lines by the addition
of 1 μg/ml puromycin to the growth medium.
Measurement of ΔΨm. ΔΨm was measured by fluorescence imaging in cells
preincubated for 40 min at room temperature (RT) with 25 nM TMRM (Invitrogen)
resuspended in Hank’s balanced salt solution (HBSS; 156 mM NaCl, 3 mM KCl,
2 mM MgSO4, 1.25 mM KH2PO4, 2 mM CaCl2, 10 mM glucose and 10 mM HEPES;
pH adjusted to 7.35 with NaOH) and kept in the media throughout the recording
time. Z-stack confocal images were acquired using a Zeiss 710 VIS CLSM confocal
microscope equipped with a META detection system and an × 40 oil immersion
objective (Zeiss, Oberkochen, Germany) and analysed using Zeiss software (Zeiss).
The 560 nm laser line was used to excite TMRM and fluorescence was measured
above 580 nm. For analysis of the effect of mitochondrial toxins on ΔΨm, images
were recorded continuously from a single focal plane. All imaging data was exported
and analysed using Volocity 3D image analysis software (PerkinElmer, Waltham,
MA, USA). To reduce background, the average intensity measurements of each
image was selected above a threshold intensity adjusted manually for each
experiment and applied to each image collected in an experiment. For each
individual experiment, average TMRM fluorescence was normalised to control cells
to allow comparison between different-day experiments. TMRM is used in the
redistribution mode to assess ΔΨm, thus a reduction in TMRM fluorescence
represents mitochondrial depolarisation. To avoid any effects of the multi drug
resistance pore on TMRM loading, in some experiments cells were treated with
5 μM cyclosporine H.
Measurement of cellular ATP content. Total cellular levels of ATP were
measured using the Vialight plus assay kit (Lonza, Verviers, Belgium) based on the
luminescence reaction that results from the oxidation of luciferin to oxyluciferin by
the firefly luciferase in an ATP-dependent manner. Approximately 500 000 cells per
well were plated in a luminescence compatible 96-well format. Cells were washed in
HBSS and lysed for 10 min in 50 μl of lysis buffer provided by the supplier. A
measure of 100 μl of ATP monitoring reagent Plus were then added to each well
and incubated at RT to generate the luminescence signal. After 2 min the
luminescent reaction was measured using a FLUOstar omega plate reader (BMG
Labtech Ltd, Ortenberg, Germany) with a specialised luminescence head. To
determine the ATP concentration, all samples were referred to an ATP standard
curve with known concentrations ranging from 1 × 10-11 M to 1 × 10-6 M and
normalised to protein concentration.
Measurement of oxygen consumption. Oxygen consumption rate was
measured using a Clark-type oxygen electrode thermostatically maintained at 37°C.
Approximately 5 × 107 cells were resuspended in respiration buffer (HBSS
containing D-glucose; 10 mM) and kept on ice before the time of recording. The
electrode was first calibrated by addition of air-saturated water assuming to contain
406 nmol O atoms/ml at 37 °C. A measure of 50 μl of cells in suspension were
added to the chamber containing 200 μl of respiration buffer and the rate of oxygen
consumption was monitored in the graph generated by Oxygraph Plus system
software (Hansatech Instruments, King's Lynn, Norfolk, UK). Once the signal value
stabilised for 1–3 min, the basal rate of oxygen consumption driven by internal
substrate oxidation was recorded from the cells. Oligomycin (2 μg/ml) was then
added to inhibit ATP synthase and reduce the rate of consumption; FCCP (1 μM)
was then added to maximise respiration and determine the maximal rate of oxygen
consumption.
For measurement of the activity of individual respiratory complexes, cells were
permeabilised with digitonin (40 μM) and resuspended in mitochondrial respiration
buffer (135 mM KCl, 10 mM NaCl, 20 mM HEPES, 0.5 mM KH2PO4, 1 mM MgCl2,
5 mM EGTA and 1.86 mM CaCl2; pH 7.1). At the time of recording, the Clark-type
oxygen electrode was thermostatically maintained at 25 °C. A measure of 50 μl of cell
suspension were added to the chamber containing already 200 μl of mitochondrial
respiration buffer with substrates for complex I (glutamate and malate 5 mM) or
complex II (succinate 5 mM with rotenone 5 μM). After recording for 1–2 min,
50 nmoles ADP were added to stimulate ATP synthesis, thereby increasing the rate of
oxygen consumption (state III respiration). Upon consumption of ADP, respiration was
reduced and rate of oxygen consumption reached a state of plateau (state IV). All
data were obtained using an Oxygraph Plus system with chart recording software.
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Measurement of cytosolic ROS. Cells plated on 25 mM glass coverslips
were loaded with the fluorescent probe DHE (80 μM; Molecular Probes, Invitrogen)
in HBSS and kept present in the solution during the experiment. No preincubation
was done for DHE to minimise accumulation of oxidised products. ROS production
was monitored in single cells using light from a Xenon arc lamp passed through a
monochromator to provide excitation light sequentially at 380 and 530 nm. Emitted
light was reflected through a 455 or 605 nm long-pass filter to a cooled CCD
camera. Rate of ROS production is proportional to the rate of increase in the ratio of
530/380 nm fluorescence. Images were captured and analysed using IQM software
from Andor (Belfast, UK).
Measurement of isolated complex I NADH dehydrogenase
activity. The NADH dehydrogenase activity of isolated complex I was measured
using the complex I enzyme activity microplate assay kit (Abcam, Cambridge, UK).
Cells cultured in 10 cm2 dish were lysed in lysis buffer provided by the manufacturer
and transferred into an eppendorf left on ice for ~ 20 min to allow protein extraction.
Samples were then centrifuged at 12 000xg for 20 min at 4 °C and total protein
concentration in the supernatant was estimated using Pierce BCA Protein Assay Kit
(Thermo Fisher Scientific). Samples were then diluted in incubation solution
(provided by the manufacturer) to reach a final protein concentration of 0.5 μg/μl. A
measure of 200 μl of each sample were transferred to each well of the microplate
containing immobilised anti-complex I antibody bound to the wells and incubated for
3 h at RT. After the incubation period, the wells were rinsed twice in 300 μl of buffer,
provided by the manufacturer, and 200 μl of assay solution containing NADH and a
reporter dye were added to each well. NADH dehydrogenase activity was
determined by measuring the oxidation of exogenous NADH to NAD+, coupled to
the 1 : 1 reduction of the reporter dye of which product concentration was
proportional to the increase in absorbance at 450 nm, measured over time using a
spectrophotometer. Complex I activity was expressed as the rate of increase in
absorbance per amount of sample loaded in the well.
Immunoblotting. Immunoblotting was performed as described previously.10
Anti-human β-actin mouse monoclonal antibody (dilution 1:10 000) was obtained
from Sigma-Aldrich; anti-Fbxo7 rabbit polyclonal antibody (dilution 1 : 1000) was
obtained from Novus Biologicals (Littleton, CO, USA); total OXPHOS cocktail mouse
monoclonal antibody (dilution 1 : 1000) was obtained from Mitosciences. Anti-
human PARP polyclonal antibody (1 : 1000) was obtained from Cell Signaling
(Danvers, MA, USA). Rabbit and mouse secondary antibodies were purchased from
Santa Cruz Biotechnology ((Santa Cruz, CA, USA) dilution 1 : 2000). All primary
and secondary antibodies were diluted in 5% (w/v) milk PBS–Tween.
Measurement of NADH and FAD++ redox indexes. NADH autofluor-
escence was measured in cells plated on 25 mM glass coverslips using an
epifluorescence-inverted microscope equipped with a × 20 fluorite objective. For
measurement of NADH in single cells, excitation light at a wavelength of 350 nm was
provided by a Xenon arc lamp, the beam passing through a monochromator (Cairn
Research, Faversham, Kent, UK). Emitted fluorescence light was reflected through a
455 nm long-pass filter to a cooled CCD camera (Retiga, QImaging, Surrey, BC,
Canada) and digitised to 12 bit resolution. All imaging data was collected and analysed
using software from Andor. FAD++ autofluorescence was measured in cells plated on
25 mM glass coverslips using a Zeiss 710 VIS CLSM confocal microscope equipped
with a META detection system and a × 40 oil immersion objective. The excitation light
was provided at a wavelength of 454 nm and fluorescence was measured from 505–
550 nm. Illumination intensity was kept to a minimum (at 0.1–0.2% of laser output) to
avoid phototoxicity and the pinhole set to give an optical slice of ~ 2 μm. Basal
autofluorescence was normalised between the minimal signal (set to 0%) and maximal
signal (set to 100%), generated in response to the respiratory inhibitor NaCN (1 mM)
and the uncoupler FCCP (1 μM), respectively.
Measurement of free cytosolic magnesium. For measurements of
[Mg2+]c, cells were loaded for 30 min at RT with 5 μM Mag-Fura-AM (Molecular
Probes, Invitrogen) and 0.005% pluronic acid in HBSS. Mag-Fura fluorescence was
monitored in single cells using excitation light provided by a Xenon arc lamp, the
beam passing through a monochromator at 340 and 380 nm (Cairn Research, Kent,
UK). Emitted fluorescence light was reflected through a 515 nm long-pass filter to a
cooled CCD camera (Retiga, QImaging, Canada) and digitised to 12 bit resolution.
All imaging data were collected and analysed using software from Andor (Belfast,
UK). Traces, obtained using the cooled CCD imaging system, are presented as the
ratio of excitation at 340 and 380 nm, both with emission at 4515 nm.
PARP activity. PARP activity was determined using the HT Colorimetric PARP/
Apoptosis Assay from Trevigen. The kit is an ELISA that detects PAR deposited onto
immobilised histone proteins. Cells were grown on a 24-well plate and treated with
DPQ 10 μM or vehicle (DMSO) for 24 h. Cells were washed with PBS and lysates
were prepared using the cell extraction buffer provided. Protein concentration was
estimated using BCA Protein Assay kit and lysates were diluted with cell lysis buffer to
a concentration of 25 ng/μl for fibroblasts and 8 ng/μl for SHSY5Y cells. A measure of
25 μl were then transferred in duplicate to a well of the ELISA plate and the assay was
performed following manufacturer instructions. PARP activity correlates with the
absorbance of the colorimetric signal generated, which was quantified at 450 nm using
a FLUOstar Omega Microplate Reader (BMG Labtech Ltd).
Measurement of cellular NAD+ levels. Intracellular NAD+ levels were
measured using a colorimetric cell-based assay kit (Cayman Chemical). Cells were
cultured in a 96-well plate and resuspended in lysis buffer, provided by the
manufacturer. After 30 min of gentle shaking at RT, the plate was centrifuged at
1000 × g for 10 min at 4 °C and 100 μl of each cell lysate were transferred into
corresponding wells of a new plate. A measure of 100 μl of reaction solution were
added to each well and incubated with gentle shaking at RT. After 1.5 h, the
absorbance in each well was measured using a microplate reader at wavelength of
450 nm. The NAD+ concentration in each sample was referred to a standard curve
with known concentrations of NAD+ and normalised to protein concentration.
Statistical analysis. Statistical analysis was performed using GraphPad Prism
6 software (La Joya, CA, USA). Data were analysed by Student's t-test or ANOVA
followed by Tukey’s test correction, and statistical significance is expressed as
* Po0.05, **Po0.01, ***Po0.005. Data were generated from a minimum of three
independent experiments, and for all graphs, error bars represent mean± S.E.M.
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